Gildeuretinol (ALK-001)
Stargardt disease
Key Facts
About Alkeus Pharmaceuticals
Alkeus Pharmaceuticals is a clinical-stage biotech advancing an oral investigational therapy, gildeuretinol, designed to address the root cause of retinal degeneration by inhibiting toxic vitamin A dimer formation. The company has active Phase 3 trials (TEASE) in Stargardt disease and a Phase 2/3 trial (SAGA) in geographic atrophy, targeting significant unmet needs in ophthalmology. Led by an experienced team with a track record in rare disease drug development and commercialization, Alkeus is positioned as a potential first-mover in treating Stargardt disease. The company operates as a private, pre-revenue entity with a focused pipeline and a clear mechanistic approach to sight preservation.
View full company profileAbout Alkeus Pharmaceuticals
Alkeus Pharmaceuticals is a clinical-stage biotech advancing an oral investigational therapy, gildeuretinol, designed to address the root cause of retinal degeneration by inhibiting toxic vitamin A dimer formation. The company has active Phase 3 trials (TEASE) in Stargardt disease and a Phase 2/3 trial (SAGA) in geographic atrophy, targeting significant unmet needs in ophthalmology. Led by an experienced team with a track record in rare disease drug development and commercialization, Alkeus is positioned as a potential first-mover in treating Stargardt disease. The company operates as a private, pre-revenue entity with a focused pipeline and a clear mechanistic approach to sight preservation.
View full company profileTherapeutic Areas
Other Stargardt disease Drugs
| Drug | Company | Phase |
|---|---|---|
| KIO-301 | Kiora Pharmaceuticals | Preclinical |
| EIR-0205 | EIR Biopharma | Preclinical |
| Emixustat HCl | Kubota Vision | Phase 3 |
| MCO-010 | Nanoscope Therapeutics | Phase 2 |
| SB-007 | SpliceBio | Phase 1/2 |
| LBS-008 | Lin BioScience | Phase 3 |
| OCU410ST | Ocugen | Phase 2/3 |
| ABO-504 | Abeona Therapeutics | Preclinical |